Ligand Pharmaceuticals Incorporated (LGND) : Ligand Pharmaceuticals Incorporated (LGND) had a healthy money flow of $3.68 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $10.79 million, whereas, investors only sold shares worth $7.11 million on downticks. The stock closed the day with an up-down ratio of 1.52.The money flow in the block trades to the tune of $4.21 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $4.21 million worth of transactions were on upticks. Ligand Pharmaceuticals Incorporated (LGND) stock slid $0.47 intraday and traded at 113.47, a change of -0.41% over previous days close. However, for the week, the company shares are -7.97% compared to previous weeks close.
Ligand Pharmaceuticals Incorporated has lost 3.4% in the last five trading days and dropped 9.97% in the last 4 weeks. Ligand Pharmaceuticals Incorporated has dropped 5.17% during the last 3-month period . Year-to-Date the stock performance stands at 4.66%.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): The stock opened at $114.02 on Monday but the bulls could not build on the opening and the stock topped out at $114.74 for the day. The stock traded down to $113.20 during the day, due to lack of any buying support eventually closed down at $113.47 with a loss of -0.41% for the day. The stock had closed at $113.94 on the previous day. The total traded volume was 280,156 shares.
In a related news, Foehr Matthew W, officer (President and COO) of Ligand Pharmaceuticals Inc, unloaded 12,500 shares at an average price of $122.14 on August 5, 2016. The total amount of the transaction was worth $1,526,750, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Companys technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.